P0695 Efficacy and tolerance of two dual therapy guidelines (darunavir/cobicistat + 3TC and dolutegravir + 3TC) in pretreated patients with HIV infection Antonia Perez Saez1, Noelia Corominas2, Maria Isabel Garcia Del Valle*1, Sergio Guillen3, Elisa Martinez Alfaro3, Fernando Mateos3, Esperanza Merino4, V. Boix4, Jose Ramón Barberá5, Fernando Cuadra6, Jose Javier Blanch3, Juan Carlos Segura3, Onofre Martinez7, Joaquín Portilla4, Enrrique Bernal8

1 Hospital general , 2 Hospital general Villarrobledo, 3 Hospital General , Albacete, , 4 Hospital Alicante, Alicante, Spain, 5 Hospital Centro, 6 Complejo hospitalario de Toledo, 7 Hospital de Cartagena, 8 Hospital Reina Sofia Background: The objective of the study is to assess the efficacy and safety after the simplification of antiretroviral treatment based on triple therapy to lamivudine (3TC) + Enhanced Protease Inhibitor (PI) or Lamivudine (3TC) + Integrase inhibitor in several hospital centers Materials/methods: Prospective multicenter study of eight spanish hospitals. We collected sociodemographic data, causes of change to biterapia, viral load as well as secondary. Results: Patients were divided into two treatment branches. First: Darunavir / cobicistat (Rezolsta) + 3TC and second: Dolutegravir (Tivicay) + 3TC. 123 patients were included in the study: 89 in the first group and 34 in the second group. The mean number of years of HIV infection in both groups was 17.89 and most had received more than 7 antiretroviral treatments. Both groups were followed up for 23 months.In the DRV / c + 3TC group, we found 89 patients, whom 56.3% were women and 78% men, with an average age of 51.48 years. The change to bitherapy in 30 patients was because of toxicity or adverse effects, in 33 cases to simplify treatment and in 9 because of virological failure. At the beginning 89.8% had undetectable viral load, and after an average of 18 months, it increased to 95.5%. With regard to CD4, they go from an average of 926.87 to 749.43. Only 11 patients had some adverse effect, having to stop treatment, most of them due to toxicity.In the DTV + 3TC group, there were 34 patients 43.8% were women and 22%men) with an average age of 56.18 years. The change to biterapia in 12 patients was made for treatment simplification and in 10 due to the adverse effect of previous treatment. An undetectable viral load was achieved in 100% of the cases after therapy with an average of 12 months of follow- up. The treatment only had to be suspended in 5 patients due to adverse effects. Conclusions: Dual therapy Darunavir / cobicistat + 3TC and Dolutegravir + 3TC, is proposed as an effective therapy in pretreated patients with high virological efficacy. No differences in efficacy or in tolerance between both have been observed.

29TH ECCMID 13-16 APRIL 2019 AMSTERDAM, NETHERLANDS POWERED BY M-ANAGE.COM